| 2025 |
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial |
Articolo in rivista |
Vai |
| 2025 |
Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis |
Articolo in rivista |
Vai |
| 2025 |
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis |
Articolo in rivista |
Vai |
| 2025 |
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment |
Articolo in rivista |
Vai |
| 2025 |
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis |
Articolo in rivista |
Vai |
| 2025 |
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events |
Articolo in rivista |
Vai |
| 2025 |
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab |
Articolo in rivista |
Vai |
| 2025 |
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab |
Articolo in rivista |
Vai |
| 2025 |
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis |
Articolo in rivista |
Vai |
| 2025 |
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT) |
Articolo in rivista |
Vai |
| 2025 |
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study |
Articolo in rivista |
Vai |
| 2025 |
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2025 |
Hepatocellular carcinoma in people living with HIV |
Articolo in rivista |
Vai |
| 2025 |
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab |
Articolo in rivista |
Vai |
| 2025 |
Establishing hepatic decompensation as a meaningful clinical outcome during systemic therapy for hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2025 |
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2025 |
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence |
Articolo in rivista |
Vai |
| 2025 |
Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison |
Articolo in rivista |
Vai |
| 2025 |
354P A multimodal deep learning model for prediction of early progression in patients with advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab |
Abstract in atti di convegno pubblicato in volume |
Vai |
| 2025 |
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab |
Articolo in rivista |
Vai |
| 2025 |
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study |
Articolo in rivista |
Vai |
| 2025 |
Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment |
Lettera |
Vai |
| 2025 |
The application of artificial intelligence-based tools in the management of hepatocellular carcinoma: current status and future perspectives |
Articolo in rivista |
Vai |
| 2025 |
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study |
Articolo in rivista |
Vai |
| 2025 |
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies |
Articolo in rivista |
Vai |
| 2024 |
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death |
Articolo in rivista |
Vai |
| 2024 |
Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review |
Articolo in rivista |
Vai |
| 2024 |
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction |
Articolo in rivista |
Vai |
| 2024 |
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis |
Articolo in rivista |
Vai |
| 2024 |
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma |
Articolo in rivista |
Vai |
| 2024 |
Evaluating the predictive performance of the elderly patient calculator TIPS score in a North American cohort |
Articolo in rivista |
Vai |
| 2024 |
The Application of Large Language Models in Gastroenterology: A Review of the Literature |
Articolo in rivista |
Vai |
| 2024 |
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study |
Articolo in rivista |
Vai |
| 2024 |
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies |
Articolo in rivista |
Vai |
| 2024 |
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab |
Articolo in rivista |
Vai |
| 2024 |
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis |
Review essay (rassegna critica) |
Vai |
| 2024 |
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours |
Articolo in rivista |
Vai |
| 2024 |
Reply to: “irLI or not irLI: That is the question” |
Lettera |
Vai |
| 2024 |
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice |
Review essay (rassegna critica) |
Vai |
| 2024 |
Initial uptake of durvalumab with or without tremelimumab for advanced hepatocellular carcinoma in routine clinical practice: Preliminary results of the international DT-real study |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2023 |
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2023 |
Expert opinion vs. meta-analysis: To be or not to be? |
Lettera |
Vai |
| 2023 |
Reply |
Lettera |
Vai |
| 2023 |
The price and value of therapeutic synergy in liver cancer |
Nota o commento |
Vai |
| 2023 |
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept |
Review essay (rassegna critica) |
Vai |
| 2023 |
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs |
Articolo in rivista |
Vai |
| 2023 |
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon |
Nota o commento |
Vai |
| 2023 |
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study |
Articolo in rivista |
Vai |
| 2023 |
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis |
Articolo in rivista |
Vai |
| 2023 |
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2022 |
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence |
Articolo in rivista |
Vai |
| 2022 |
Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data |
Articolo in rivista |
Vai |
| 2022 |
Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data |
Articolo in rivista |
Vai |
| 2022 |
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model |
Articolo in rivista |
Vai |
| 2022 |
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib |
Articolo in rivista |
Vai |
| 2022 |
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices |
Articolo in rivista |
Vai |
| 2022 |
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints |
Articolo in rivista |
Vai |
| 2022 |
Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis |
Articolo in rivista |
Vai |
| 2022 |
COSMIC-312: mounting immunotherapy enigmas for hepatocellular carcinoma |
Lettera |
Vai |
| 2022 |
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison |
Articolo in rivista |
Vai |
| 2022 |
Reply |
Lettera |
Vai |
| 2022 |
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation |
Articolo in rivista |
Vai |
| 2022 |
Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals |
Articolo in rivista |
Vai |
| 2022 |
Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC |
Articolo in rivista |
Vai |
| 2022 |
AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD |
Articolo in rivista |
Vai |
| 2022 |
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment |
Articolo in rivista |
Vai |
| 2021 |
Competing-risk analysis of coronavirus disease 2019 in-hospital mortality in a Northern Italian centre from SMAtteo COvid19 REgistry (SMACORE) |
Articolo in rivista |
Vai |
| 2021 |
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis |
Articolo in rivista |
Vai |
| 2021 |
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use |
Articolo in rivista |
Vai |
| 2021 |
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma |
Articolo in rivista |
Vai |
| 2021 |
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? |
Articolo in rivista |
Vai |
| 2021 |
Identification of clinical phenotypes and related survival in patients with large hccs |
Articolo in rivista |
Vai |
| 2021 |
Biliary complications after liver transplantation: current perspectives and future strategies |
Review essay (rassegna critica) |
Vai |
| 2021 |
Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients |
Articolo in rivista |
Vai |
| 2021 |
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 |
Articolo in rivista |
Vai |
| 2021 |
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study |
Articolo in rivista |
Vai |
| 2021 |
Impact of biliary stents on the diagnostic accuracy of EUS-guided fine-needle biopsy of solid pancreatic head lesions: A multicenter study |
Articolo in rivista |
Vai |
| 2021 |
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials |
Articolo in rivista |
Vai |
| 2021 |
Consequences of Extended Spectrum Beta-Lactamase–Producing Enterobacteriaceae and Methicillin-Resistant Staphylococcus aureus Carriage in Awaiting Liver Transplant Patients |
Articolo in rivista |
Vai |
| 2021 |
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy |
Articolo in rivista |
Vai |
| 2021 |
Systemic therapies for hepatocellular carcinoma: The present and the future |
Articolo in rivista |
Vai |
| 2021 |
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals |
Articolo in rivista |
Vai |
| 2020 |
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib |
Articolo in rivista |
Vai |
| 2020 |
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis |
Articolo in rivista |
Vai |
| 2020 |
Through-the-needle biopsy of pancreatic cystic lesions: stronger evidences of higher diagnostic yield compared with cytology |
Articolo in rivista |
Vai |
| 2020 |
Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors |
Articolo in rivista |
Vai |
| 2020 |
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib |
Articolo in rivista |
Vai |
| 2020 |
Diagnostic performance of endoscopic ultrasound through-the-needle microforceps biopsy of pancreatic cystic lesions: Systematic review with meta-analysis |
Articolo in rivista |
Vai |
| 2020 |
Efficacy of lumen-apposing metal stents or self-expandable metal stents for endoscopic ultrasound-guided choledochoduodenostomy: A systematic review and meta-analysis |
Articolo in rivista |
Vai |
| 2020 |
Biochemical biomarkers of NAFLD/NASH |
Capitolo o Saggio |
Vai |
| 2020 |
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease |
Articolo in rivista |
Vai |
| 2020 |
The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease |
Articolo in rivista |
Vai |
| 2019 |
Outcomes of hepatocellular carcinoma patients treated with sorafenib: A meta-analysis of Phase III trials |
Articolo in rivista |
Vai |
| 2019 |
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Articolo in rivista |
Vai |
| 2019 |
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients |
Abstract in atti di convegno pubblicato in rivista |
Vai |
| 2019 |
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis |
Articolo in rivista |
Vai |
| 2019 |
Pharmacological therapy of non-alcoholic fatty liver disease: What drugs are available now and future perspectives |
Articolo in rivista |
Vai |
| 2019 |
The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: Screening issue and future perspectives |
Articolo in rivista |
Vai |
| 2018 |
Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? |
Articolo in rivista |
Vai |
| 2018 |
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? |
Articolo in rivista |
Vai |
| 2018 |
Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? |
Articolo in rivista |
Vai |
